The epinephrine market is primarily driven by the increasing prevalence of anaphylaxis reactions globally. Anaphylaxis is a severe, potentially life-threatening allergic reaction. It occurs suddenly after exposure to an allergen like food, insect stings, medicines, etc. The severity of symptoms and their onset vary from person to person, ranging from minor reactions to death.
Request a Sample Copy of the Report @ https://www.coherentmarketinsights.com/insight/request-sample/2401
According to a study, the lifetime prevalence of anaphylaxis is estimated to be around 0.05% to 3%, and its incidence has been increasing over the past few decades. Moreover, the delayed availability of emergency epinephrine devices increases the risk of mortality in patients suffering from anaphylaxis reaction. This drives the demand for portable epinephrine injection devices for emergency treatment.
Market Trends:
Increasing adoption of epinephrine auto-injectors
There is a growing trend of adoption of reusable and prefilled epinephrine auto-injectors among people with known severe allergies as well as first-time users. These devices are easy-to-use. These provide step-by-step instructions for use during an allergic reaction. Moreover, auto-injectors reduce delays in administration during emergency conditions.
New product approvals and launches
Market players are focused on launching innovative products with improved features. The features include accuracy in dosage delivery and longer shelf-life. For instance, in August 2020, Endo Pharmaceuticals received approval from the FDA for ANTARES. This is a prefilled epinephrine auto-injector with extended shelf-life.
Epinephrine Market Report Coverage
|
Report Coverage |
Details |
|
Market Revenue in 2024 |
$2.91 billion |
|
Estimated Value by 2031 |
$6.27 billion |
|
Growth Rate |
Poised to grow at a CAGR of 11.6% |
|
Historical Data |
2019–2023 |
|
Forecast Period |
2024–2031 |
|
Forecast Units |
Value (USD Million/Billion) |
|
Report Coverage |
Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
|
Segments Covered |
By Product Type, By Application, By Distribution Channel |
|
Geographies Covered |
North America, Europe, Asia Pacific, and Rest of World |
|
Growth Drivers |
• Rising Prevalence of Allergic Reactions • Growing Adoption of Epinephrine Autoinjectors |
|
Restraints & Challenges |
• High treatment costs • Recall of product batches |
Market Opportunities
Increasing Incidence of Anaphylaxis
The increasing prevalence of allergies and rising incidence of anaphylaxis are expected to drive the demand for epinephrine auto-injectors. Anaphylaxis occurs within minutes of exposure to an allergy trigger. According to recent estimates, anaphylaxis affects 1-5% of the population. Its incidence has increased significantly over the past few decades. Auto-injectors are now considered the standard of care for treating anaphylaxis due to their ease of use. Increase in anaphylaxis cases is expected to support the uptake of epinephrine auto-injectors during the forecast period.
Immediate Delivery Available | Buy This Premium Research Report: https://www.coherentmarketinsights.com/insight/buy-now/2401
Investments in Technology Advancements
Epinephrine delivery devices are advancing with new technologies. These technologies enhance safety, accuracy, and ease of use. For instance, wearable and hands-free epinephrine auto-injectors are being developed that can administer the dose through clothing. Bluetooth and audio guidance features are also being incorporated in devices to provide visual and voice instructions. Furthermore, reusable auto-injectors are in the pipeline that can administer multiple consistent doses. Such innovations are expected to improve treatment outcomes and compliance for patients at risk of anaphylaxis. The growing investments in advanced epinephrine delivery technologies are poised to present attractive opportunities in the market.
Key Market Takeaways
The global epinephrine market is anticipated to witness a CAGR of 11.6% during the forecast period 2024-2031. This is owing to rising environmental allergies and food allergies globally.
On the basis of product type, the auto-injectors segment is expected to hold a dominant position, accounting for over 70% market share. This is owing to their ease of use during anaphylaxis emergencies.
By application, the anaphylaxis segment is expected to dominate with over 80% share as epinephrine is the first line treatment for anaphylaxis.
On the basis of distribution channel, the hospital pharmacy segment is expected to hold the major share due to higher patient footfall, insurance coverage, and critical condition treated.
By region, North America is expected to hold a dominant position over the forecast period. This is owing to high awareness about anaphylaxis, supportive reimbursement policies, and presence of leading players. Europe is also expected to grow at a significant rate.
Competitor Insights
- Pfizer
- Mylan Inc.
- Sanofi S.A
- ALK-Abello
Epinephrine Industry News
In 2023, Daiichi Sankyo’s subsidiary, American Regent, launched a sulfite-free epinephrine injection. This provides a safer option for patients allergic to sulphites.
The FDA’s Pulmonary-Allergy Drugs Advisory Committee reviewed ARS Pharmaceuticals’ nasal spray, Neffy, in 2023. This nasal spray is designed for emergency treatment of allergic reactions, including anaphylaxis. Neffy represents a major advancement in epinephrine delivery, offering a more convenient and non-invasive option compared to traditional auto-injectors.
FDA Approvals and Expansions: In 2023, ARS Pharmaceuticals’ nasal spray, Neffy, received the U.S. FDA acceptance for review. Such nasal sprays offer more convenient administration during emergencies.
Request For Customization: https://www.coherentmarketinsights.com/insight/request-customization/2401
Detailed Segmentation-
By Product Type
- Auto-injector
- Prefilled Syringes
- Ampoules and Vials
By Application
- Anaphylaxis
- Cardiac Arrest
- Superficial Bleeding
- Respiratory Disorders
- Others
By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
By Region
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
Find Most Trending Related Reports:
The global Prefilled Syringes Market is estimated to be valued at US$ 6.44 billion in 2023 and is expected to exhibit a CAGR of 5.6% during the forecast period (2023-2030).
The global small molecule prefilled syringes market is estimated to be valued at US$ 18.98 Bn in 2023, and is expected to exhibit a CAGR of 5.2% during the forecast period (2023-2030).
The global subcutaneous drug delivery market is estimated to be valued at US$ 11.88 billion in 2023 and is expected to exhibit a CAGR of 9.7% during the forecast period (2023-2030).
About Us:
Coherent Market Insights is a global market intelligence and consulting organization that provides syndicated research reports, customized research reports, and consulting services. We are known for our actionable insights and authentic reports in various domains including aerospace and defense, agriculture, food and beverages, automotive, chemicals and materials, and virtually all domains and an exhaustive list of sub-domains under the sun. We create value for clients through our highly reliable and accurate reports. We are also committed in playing a leading role in offering insights in various sectors post-COVID-19 and continue to deliver measurable, sustainable results for our clients.
Contact Us:
Mr. Shah
Senior Client Partner – Business Development
Coherent Market Insights
Phone:
US: +1-650-918-5898
UK: +44-020-8133-4027
AUS: +61-2-4786-0457
India: +91-848-285-0837
Email: sales@coherentmarketinsights.com
